The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Cancer in the Transplant Recipient
Open accessAbstract
Malignancy has become one of the three major causes of death after transplantation in the past decade and is thus increasingly important in all organ transplant programs. Death from cardiovascular disease and infection are both decreasing in frequency from a combination of screening, prophylaxis, aggressive risk factor management, and interventional therapies. Cancer, on the other hand, is poorly and expensively screened for; risk factors are mostly elusive and/or hard to impact on except for the use of immunosuppression itself; and finally therapeutic approaches to the transplant recipient with cancer are often nihilistic. This article provides a review of each of the issues as they come to affect transplantation: cancer before wait-listing, cancer transmission from the donor, cancer after transplantation, outcomes of transplant recipients after a diagnosis of cancer, and the role of screening and therapy in reducing the impact of cancer in transplant recipients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
Spectrum of cancer risk among US solid organ transplant recipients
Engels, E. A., Pfeiffer, R. M., Fraumeni, J. F., Kasiske, B. L., Israni, A. K., Snyder, J. J., Wolfe, R. A., Goodrich, N. P., Bayakly, A. R., Clarke, C. A., et al. (2011) · JAMA · doi:10.1001/jama.2011.1592 · Cited by 1,524
Cancer Incidence Before and After Kidney Transplantation
Vajdic, C. M., McDonald, S. P., McCredie, M. R. E., van Leeuwen, M. T., Stewart, J. H., Law, M., Chapman, J. R., Webster, A. C., Kaldor, J. M., & Grulich, A. E. (2006) · JAMA · doi:10.1001/jama.296.23.2823 · Cited by 1,130
Self-citationLymphomas After Solid Organ Transplantation: A Collaborative Transplant Study Report
Opelz, G., & Döhler, B. (2004) · American Journal of Transplantation · doi:10.1046/j.1600-6143.2003.00325.x · Cited by 1,081
The evaluation of renal transplantation candidates: clinical practice guidelines.
Kasiske, B. L., Cangro, C. B., Hariharan, S., et al. (2001) · PubMed · Cited by 726
Cancer risk following organ transplantation: a nationwide cohort study in Sweden
Adami, J., Gäbel, H., Lindelöf, B., Ekström, K., Rydh, B., Glimelius, B., Ekbom, A., Adami, H.-O., & Granath, F. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601219 · Cited by 692
Recommendations for the Outpatient Surveillance of Renal Transplant Recipients
KASISKE, B. L., VAZQUEZ, M. A., HARMON, W. E., BROWN, R. S., DANOVITCH, G. M., GASTON, R. S., ROTH, D., SCANDLING, J. D., & SINGER, G. G. (2000) · Journal of the American Society of Nephrology · doi:10.1681/asn.v11suppl_1s1 · Cited by 634
Sirolimus and Secondary Skin-Cancer Prevention in Kidney Transplantation
Euvrard, S., Morelon, E., Rostaing, L., Goffin, E., Brocard, A., Tromme, I., Broeders, N., del Marmol, V., Chatelet, V., Dompmartin, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1204166 · Cited by 593
Collett, D., Mumford, L., Banner, N. R., Neuberger, J., & Watson, C. (2010) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2010.03181.x · Cited by 501
Canadian Society of Transplantation consensus guidelines on eligibility for kidney transplantation
Knoll, G. (2005) · Canadian Medical Association Journal · doi:10.1503/cmaj.051291 · Cited by 376
European Best Practice Guidelines for Renal Transplantation (Part 2).
Berthoux, F. C., Abramowicz, D., Ekberg, H., Frei, U. A., Morales, J., Ølgaard, K., Paul, L., & Pontecelli, C. (2002) · Lund University Publications (Lund University) · Cited by 371
PRO- AND ANTI-CANCER EFFECTS OF IMMUNOSUPPRESSIVE AGENTS USED IN ORGAN TRANSPLANTATION
Guba, M., Graeb, C., Jauch, K.-W., & Geissler, E. K. (2004) · Transplantation · doi:10.1097/01.tp.0000120181.89206.54 · Cited by 360
THE EFFECT OF IMMUNOSUPPRESSION ON PRE-EXISTING CANCERS
PENN, I. (1993) · Transplantation · doi:10.1097/00007890-199304000-00011 · Cited by 340
Cancer Incidence Among Canadian Kidney Transplant Recipients
Villeneuve, P., Schaubel, D., Fenton, S., Shepherd, F., Jiang, Y., & Mao, Y. (2007) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2007.01736.x · Cited by 313
Association of CKD and Cancer Risk in Older People
Wong, G., Hayen, A., Chapman, J. R., Webster, A. C., Wang, J. J., Mitchell, P., & Craig, J. C. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008090998 · Cited by 293
Self-citationNon-melanoma skin cancer risk in the Queensland renal transplant population
Ramsay, H. M., Fryer, A. A., Hawley, C. M., Smith, A. G., Nicol, D. L., & Harden, P. N. (2002) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2002.04976.x · Cited by 277
Rapamycin: an anti-cancer immunosuppressant?
Law, B. K. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.09.009 · Cited by 252
SECTION IV: Long-term management of the transplant recipient
(2002) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/17.suppl_4.3 · Cited by 243
Transplant tumor registry: donor related malignancies
Myron Kauffman, H., McBride, M. A., Cherikh, W. S., Spain, P. C., Marks, W. H., & Roza, A. M. (2002) · Transplantation · doi:10.1097/00007890-200208150-00011 · Cited by 242
Canadian Society of Transplantation: consensus guidelines on eligibility for kidney transplantation
Knoll, G. (2005) · Canadian Medical Association Journal · doi:10.1503/cmaj.1041588 · Cited by 233
Miao, Y., Everly, J. J., Gross, T. G., Tevar, A. D., First, M. R., Alloway, R. R., & Woodle, E. S. (2009) · Transplantation · doi:10.1097/tp.0b013e3181a238f6 · Cited by 229
Alberú, J., Pascoe, M. D., Campistol, J. M., Schena, F. P., Rial, M. D. C., Polinsky, M., Neylan, J. F., Korth-Bradley, J., Goldberg-Alberts, R., & Maller, E. S. (2011) · Transplantation · doi:10.1097/tp.0b013e3182247ae2 · Cited by 224
Campbell, S. B., Walker, R., Tai, S. S., Jiang, Q., & Russ, G. R. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04004.x · Cited by 221
Donor-Transmitted Malignancies in Organ Transplantation: Assessment of Clinical Risk
Nalesnik, M. A., Woodle, E. S., DiMaio, J. M., Vasudev, B., Teperman, L. W., Covington, S., Taranto, S., Gockerman, J. P., Shapiro, R., Sharma, V., et al. (2011) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2011.03565.x · Cited by 211
Amato, R. J., Jac, J., Giessinger, S., Saxena, S., & Willis, J. P. (2009) · Cancer · doi:10.1002/cncr.24280 · Cited by 201
van Leeuwen, M. T., Webster, A. C., McCredie, M. R. E., Stewart, J. H., McDonald, S. P., Amin, J., Kaldor, J. M., Chapman, J. R., Vajdic, C. M., & Grulich, A. E. (2010) · BMJ · doi:10.1136/bmj.c570 · Cited by 194
Self-citationCancer incidence in a kidney-transplanted population
Kyllönen, L., Salmela, K. T., & Pukkala, E. (2000) · Transplant International · doi:10.1007/s001470050369 · Cited by 171
Clinical Practice Guidelines on Wait-Listing for Kidney Transplantation
Batabyal, P., Chapman, J. R., Wong, G., et al. (2012) · Transplantation · doi:10.1097/tp.0b013e3182637078 · Cited by 130
Self-citationTemsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines
Wang, Y., Wang, X.-Y., Subjeck, J. R., Shrikant, P., & Kim, H. L. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.15 · Cited by 114
Cancer Mortality in Kidney Transplantation
Kiberd, B. A., Rose, C., & Gill, J. S. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02728.x · Cited by 106
Comparison of De Novo Cancer Incidence in Australian Liver, Heart and Lung Transplant Recipients
Na, R., Grulich, A. E., Meagher, N. S., McCaughan, G. W., KEOGH, A. M., & Vajdic, C. M. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04302.x · Cited by 98
mTOR Pathway and mTOR Inhibitors as Agents for Cancer Therapy
Baldo, P., Cecco, S., Giacomin, E., Lazzarini, R., Rós, B. D. T., & Marastoni, S. (2008) · Current Cancer Drug Targets · doi:10.2174/156800908786733513 · Cited by 97
Mammalian Target of Rapamycin (mTOR) Inhibitors as Anti-Cancer Agents
Rao, R. D., Buckner, J. C., & Sarkaria, J. N. (2004) · Current Cancer Drug Targets · doi:10.2174/1568009043332718 · Cited by 89
Simeone, E., & Ascierto, P. A. (2012) · Journal of Immunotoxicology · doi:10.3109/1547691x.2012.678021 · Cited by 84
The Incidence of Cancer in a Population‐Based Cohort of Canadian Heart Transplant Recipients
Jiang, Y., Villeneuve, P. J., Wielgosz, A. T., Schaubel, D. E., Fenton, S. S. A., & Mao, Y. (2010) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02973.x · Cited by 78
Collins, M. G., Teo, E., Cole, S. R., et al. (2012) · BMJ · doi:10.1136/bmj.e4657 · Cited by 49
Wong, G., Howard, K., Webster, A. C., Chapman, J. R., & Craig, J. C. (2009) · Transplantation · doi:10.1097/tp.0b013e31819d32eb · Cited by 48
Self-citation
Cited by
The concept of immune surveillance against tumors: The first theories
Ribatti, D. (2017) · Oncotarget · doi:10.18632/oncotarget.12739 · Cited by 332
Single-center long-term analysis of combined liver-lung transplant outcomes
Freischlag, K. W., Messina, J., Ezekian, B., Mulvihill, M. S., Barbas, A., Berg, C., Sudan, D., Reynolds, J., Hartwig, M., & Knechtle, S. (2018) · Transplantation Direct · doi:10.1097/txd.0000000000000785 · Cited by 26
Metadata
- Authors
- Chapman, J. R., Webster, A. C., & Wong, G.
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2013-07-01
- Volume
- 3
- Issue
- 7
- Pages
- a015677-a015677
- ISSN
- 2157-1422 (ISSN-L)
- OpenAlex
- W2122346692
- Cited by
- 275
- References
- 37
- Type
- posted content
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.